Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
North Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan.
J Neurol Sci. 2017 Oct 15;381:62-67. doi: 10.1016/j.jns.2017.08.009. Epub 2017 Aug 8.
Definite diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy (CADASIL) is mostly done by identification of NOTCH3 mutations. We aimed to develop criteria for selecting patients suspected for CADASIL to undergo genetic testing.
All subjects were Japanese. We recruited CADASIL patients genetically diagnosed up until 2011 (n=37, Group 1) or after 2011 (n=65, Group 2), 67 young stroke patients (≤55 years old), and 53 NOTCH3-negative CADASIL-like patients. The members of Japanese research committee for hereditary cerebral small vessel disease discussed and generated the new criteria to maximize positive rate in Group 1 CADASIL patients, followed by validation of sensitivity and specificity.
In Group 1 CADASIL patients, the ages at onset excluding migraine were distributed widely (37-74 years old) and bimodal (<55 and >55 years old). Frequencies of an autosomal dominant family history and vascular risk factor(s) were 73 and 65%, respectively. From these findings, the panel considered appropriate cut-off values and weighting for each item. In CADASIL Group 1 versus young stroke controls, the sensitivity and specificity of the new criteria were 97.3% and 80.6%, respectively. However, in CADASIL Group 2 versus NOTCH3-negative controls, the sensitivity and specificity were 96.9% and 7.5%, respectively. Forty mutations of NOTCH3 distributed in exons 2-8, 11, 14, 18, 19, and 21 were identified in this study. Ten mutations were unreported ones.
We propose the new criteria of high sensitivity, which will help physicians to assess the need for genetic testing.
通过鉴定 NOTCH3 突变,对脑常染色体显性动脉病伴皮质下梗死和白质脑病(CADASIL)进行明确诊断。我们旨在制定选择疑似 CADASIL 患者进行基因检测的标准。
所有研究对象均为日本人。我们招募了截至 2011 年(第 1 组,n=37)或 2011 年后(第 2 组,n=65)确诊的 CADASIL 患者、67 名年轻卒中患者(≤55 岁)和 53 名 NOTCH3 阴性 CADASIL 样患者。日本遗传性脑小血管病研究委员会的成员讨论并制定了新的标准,以使第 1 组 CADASIL 患者的阳性率最大化,随后验证了其敏感性和特异性。
在第 1 组 CADASIL 患者中,发病年龄(排除偏头痛)分布广泛(37-74 岁)且呈双峰分布(<55 岁和>55 岁)。常染色体显性家族史和血管危险因素的发生率分别为 73%和 65%。根据这些发现,专家组考虑了每个项目的适当截断值和权重。在 CADASIL 第 1 组与年轻卒中对照组之间,新准则的敏感性和特异性分别为 97.3%和 80.6%。然而,在 CADASIL 第 2 组与 NOTCH3 阴性对照组之间,敏感性和特异性分别为 96.9%和 7.5%。本研究共鉴定出 NOTCH3 的 40 种突变,分布于外显子 2-8、11、14、18、19 和 21。其中 10 种突变为未报道的突变。
我们提出了一种高敏感性的新标准,这将有助于医生评估基因检测的必要性。